How Ph.D was paid
$6.5M in total for fiscal 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Dr. Jerel Banks, M.D. Ph.DChairman and Chief Executive Officer | $667,000 | $550,275 | $5,252,400 | $46,644 | $6,516,319 |
| Megan BostonChief Financial Officer, Secretary | $531,900 | $281,380 | $2,334,400 | $19,757 | $3,167,437 |
| Sophie MukadamChief Operating Officer | $500,000 | $300,000 | $5,836,000 | $70,443 | $6,706,443 |
What changed and why
- $6.5MDr. Banks’ total compensation was $6,516,319 in fiscal 2026, compared with $25,865,036 in fiscal 2025.
- Fiscal 2026 bonuses were half-year cash bonuses for July 1 through December 31, 2025; the company transitioned to calendar-year reviews for 2026.
- November 2025 option grants covered 450,000 shares for Dr. Banks, 200,000 for Megan Boston, and 500,000 for Sophie Mukadam.
- The November 2025 options vest in 16 substantially equal quarterly installments, subject to continued service.
- $5.3MFiscal 2026 option awards were $5,252,400 for Dr. Banks, $2,334,400 for Megan Boston, and $5,836,000 for Sophie Mukadam.
Other Benitec Biopharma proxy statements
- 2025 proxy statement
Dr. Jerel Banks, M.D. Ph.D paid $25.9M (+719% on the year).
Filed Oct 14, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.